Acadian Asset Management Portfolio holdings
AUM
$48.4B
1-Year Return
32.04%
This Quarter Return
+8.62%
1 Year Return
+32.04%
3 Year Return
+133.69%
5 Year Return
+272.69%
10 Year Return
+761.99%
AUM
$32.2B
AUM Growth
-$282M
(-0.87%)
Cap. Flow
-$1.8B
Cap. Flow
% of AUM
-5.59%
Top 10 Holdings %
Top 10 Hldgs %
23.59%
Holding
2,410
New
656
Increased
561
Reduced
741
Closed
336
Top Buys
| 1 |
Ericsson
ERIC
|
+$303M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$264M |
| 3 |
Citigroup
C
|
+$196M |
| 4 |
Fortinet
FTNT
|
+$162M |
| 5 |
Infosys
INFY
|
+$144M |
Top Sells
| 1 |
Pinduoduo
PDD
|
+$419M |
| 2 |
NVIDIA
NVDA
|
+$417M |
| 3 |
Amazon
AMZN
|
+$388M |
| 4 |
Meta Platforms (Facebook)
META
|
+$288M |
| 5 |
CRH
CRH
|
+$272M |
Sector Composition
| 1 | Technology | 34.81% |
| 2 | Financials | 16.08% |
| 3 | Communication Services | 9.48% |
| 4 | Consumer Discretionary | 9.1% |
| 5 | Healthcare | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Warner Bros
WBD
$30B
| $17K | ﹤0.01% |
2,098
-69,937
| -97% | -$567K |
|
2002
Cullinan Oncology
CGEM
$389M
| $16K | ﹤0.01% |
+956
| New | +$16K |
|
2003
Krispy Kreme
DNUT
$522M
| $16K | ﹤0.01% |
+1,521
| New | +$16K |
|
2004
Evergy
EVRG
$16.4B
| $16K | ﹤0.01% |
260
| – | – |
|
2005
OGE Energy
OGE
$8.82B
| $16K | ﹤0.01% |
406
| – | – |
|
2006
Rocky Brands
RCKY
$218M
| $16K | ﹤0.01% |
+513
| New | +$16K |
|
2007
Altimmune
ALT
$328M
| $15K | ﹤0.01% |
+2,506
| New | +$15K |
|
2008
Anterix
ATEX
$399M
| $15K | ﹤0.01% |
+417
| New | +$15K |
|
2009
AMCON Distributing
DIT
$76.1M
| $15K | ﹤0.01% |
107
-35
| -25% | -$4.91K |
|
2010
Heron Therapeutics
HRTX
$198M
| $15K | ﹤0.01% |
7,601
-28,861
| -79% | -$57K |
|
2011
Martin Midstream Partners
MMLP
$123M
| $15K | ﹤0.01% |
4,266
-15,693
| -79% | -$55.2K |
|
2012
Treehouse Foods
THS
$882M
| $15K | ﹤0.01% |
+374
| New | +$15K |
|
|
CTHR
2013
DELISTED
Charles & Colvard Ltd
CTHR
| $15K | ﹤0.01% |
8,631
-11,160
| -56% | -$19.4K |
|
2014
Chubb
CB
$110B
| $14K | ﹤0.01% |
50
-11,448
| -100% | -$3.21M |
|
2015
Cyclacel Pharmaceuticals
CYCC
$14.7M
| $14K | ﹤0.01% |
60
| – | – |
|
2016
Cytokinetics
CYTK
$6.07B
| $14K | ﹤0.01% |
+280
| New | +$14K |
|
2017
EyePoint Pharmaceuticals
EYPT
$945M
| $14K | ﹤0.01% |
+1,864
| New | +$14K |
|
2018
Goldman Sachs BDC
GSBD
$1.31B
| $14K | ﹤0.01% |
1,019
-110
| -10% | -$1.51K |
|
|
TVRD
2019
Tvardi Therapeutics, Inc. Common Stock
TVRD
$299M
| $13K | ﹤0.01% |
1,264
-6,161
| -83% | -$63.4K |
|
2020
FIGS
FIGS
$1.09B
| $12K | ﹤0.01% |
+1,882
| New | +$12K |
|
2021
DT Midstream
DTM
$10.9B
| $11K | ﹤0.01% |
+150
| New | +$11K |
|
2022
Madison Square Garden
MSGS
$4.93B
| $11K | ﹤0.01% |
55
| – | – |
|
|
PHLT
2023
Performant Healthcare, Inc. Common Stock
PHLT
$605M
| $11K | ﹤0.01% |
+3,117
| New | +$11K |
|
2024
Deswell Industries
DSWL
$67.7M
| $10K | ﹤0.01% |
4,212
| – | – |
|
2025
Mexco Energy
MXC
$17.2M
| $10K | ﹤0.01% |
845
-1,277
| -60% | -$15.1K |
|